The antiarrhythmic medicine sales in Australia have demonstrated a downward trend from 2013 to 2023. Initially, from 2013 to 2015, the market maintained stable sales. However, in 2016, sales dropped significantly by 50%, establishing a new lower level. Since 2016, sales have plateaued at this reduced level, maintaining consistent figures through to 2023. The CAGR for the period from 2016 to 2023 has stayed at 0%, indicating no further growth or decline.
Future trends to watch for:
- Potential disruptions from new technologies or treatments in cardiology.
- Regulatory changes influencing market dynamics.
- Shifts in consumer preferences or demographics affecting demand.
